Key clinical point: Once-monthly galcanezumab significantly reduced the frequency of migraine-associated symptoms and migraine headache severity in patients with episodic migraine.
Major finding: Moderate-to-severe migraine headache days (MHD) reduced significantly with 240 mg galcanezumab (difference in least-squares mean change from baseline [Δ] −1.8 days, 95% CI −2.5 to −1.2) and 120 mg (Δ −1.9 days, 95% CI −2.5 to −1.2) vs placebo, with 240 mg galcanezumab also leading to significant reductions in the proportion of monthly MHD during menstrual periods (P = .04), and MHDswith nausea or vomiting (P = .02).
Study details: This was a secondary analysis of a phase 2 trial including 440 patients with episodic migraine who were randomly assigned to receive monthly galcanezumab (240 or 120 mg) or placebo.
Disclosures: This study was funded by Eli Lilly Japan K.K. Two authors declared being employees and minor shareholders of Eli Lilly. Two authors reported receiving personal fees for speaker or consulting services from Eli Lilly Japan K.K. and other sources.
Source: Igarashi H et al. Galcanezumab effects on migraine severity and symptoms in Japanese patients with episodic migraine: Secondary analysis of a phase 2 randomized trial. Neurol Ther. 2022 (Oct 20). Doi: 10.1007/s40120-022-00410-3